ADL-5747

ADL-5747 is a small molecule, orally available and selective delta (δ) opioid receptor agonist that was developed for the treatment of pain, including chronic inflammatory and neuropathic pain. It demonstrated efficient analgesic effects in preclinical models by activating δ-opioid receptors, particularly those expressed on peripheral Nav1.8-positive neurons. Unlike classical opioids such as morphine, ADL‑5747 is selective for the delta receptor and does not induce typical side effects like hyperlocomotion or receptor internalization seen with other δ agonists. The drug reached phase II clinical trials for pain indications but its development was discontinued after failing to meet efficacy endpoints[1][5][6][7].

Other names

N,N-diethyl-3-hydroxy-4-(spiro(chromene-2,4'-piperidine)-4-yl)benzamideUNII 24QBI4WA54UNII24QBI4WA54UNII-24QBI4WA54